GSE221512 WCRC-25: A novel luminal Invasive Lobular Carcinoma cell line model
In conclusion, we report WCRC-25 as a novel ILC cell line with much promise as a valuable research tool to advance our understanding of ILC and its therapeutic vulnerabilities. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - December 20, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in breast and gynecologic cancers
Cancer Res Commun. 2023 Dec 19. doi: 10.1158/2767-9764.CRC-23-0275. Online ahead of print.ABSTRACTWnt ligand WNT4 is critical in female reproductive tissue development, with WNT4 dysregulation linked to related pathologies including breast cancer (invasive lobular carcinoma, ILC) and gynecologic cancers. WNT4 signaling in these contexts is distinct from canonical Wnt signaling yet inadequately understood. We previously identified atypical intracellular activity of WNT4 (independent of Wnt secretion) regulating mitochondrial function, and herein examine intracellular functions of WNT4. We further examine how convergent mech...
Source: Cell Research - December 19, 2023 Category: Cytology Authors: Joseph L Sottnik Madeleine T Shackleford Sydney K Robinson Fabian R Villagomez Shaymaa Bahnassy Steffi Oesterreich Junxiao Hu Zeynep Madak-Erdogan Rebecca B Riggins Bradley R Corr Linda S Cook Lindsey S Trevi ño Benjamin G Bitler Matthew J Sikora Source Type: research
Impact of pre-operative MRI on surgical management of screening digital breast tomosynthesis-detected invasive lobular carcinoma
ConclusionMRI led to the detection of additional disease, thus impacting surgical management, in one-fifth of patients with ILC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 16, 2023 Category: Cancer & Oncology Source Type: research
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma
CONCLUSION: In ET-refractory HR+ HER2-negative mILC, single-agent CAP demonstrated superior PFS compared to TAX. Our findings highlight the potential benefit of CAP in this patient subset, warranting further investigation through prospective trials.PMID:38070191 | DOI:10.1093/oncolo/oyad317 (Source: The Oncologist)
Source: The Oncologist - December 9, 2023 Category: Cancer & Oncology Authors: Jason A Mouabbi Wei Qaio Yu Shen Akshara Singareeka Raghavendra Debasish Tripathy Rachel M Layman Source Type: research
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma
CONCLUSION: In ET-refractory HR+ HER2-negative mILC, single-agent CAP demonstrated superior PFS compared to TAX. Our findings highlight the potential benefit of CAP in this patient subset, warranting further investigation through prospective trials.PMID:38070191 | DOI:10.1093/oncolo/oyad317 (Source: The Oncologist)
Source: The Oncologist - December 9, 2023 Category: Cancer & Oncology Authors: Jason A Mouabbi Wei Qaio Yu Shen Akshara Singareeka Raghavendra Debasish Tripathy Rachel M Layman Source Type: research
Clinicopathological profile of breast cancer from Chhattisgarh India: A single-center hospital-based study
CONCLUSION: The clinico-epidemio and histological profile of breast cancer in Chhattisgarh is similar to other parts of India. Scarff Bloom Richardson Grade was predominantly grade 2 in 46.25% (37/80) contrary to Grade III (70%) in other series from India.PMID:38024932 | PMC:PMC10657078 | DOI:10.4103/jfmpc.jfmpc_2315_22 (Source: Primary Care)
Source: Primary Care - November 29, 2023 Category: Primary Care Authors: Niraj Kumar Srivastava Sunita Singh Debajyoti Mohanty Nughat Hussain Source Type: research
Clinicopathological profile of breast cancer from Chhattisgarh India: A single-center hospital-based study
CONCLUSION: The clinico-epidemio and histological profile of breast cancer in Chhattisgarh is similar to other parts of India. Scarff Bloom Richardson Grade was predominantly grade 2 in 46.25% (37/80) contrary to Grade III (70%) in other series from India.PMID:38024932 | PMC:PMC10657078 | DOI:10.4103/jfmpc.jfmpc_2315_22 (Source: Primary Care)
Source: Primary Care - November 29, 2023 Category: Primary Care Authors: Niraj Kumar Srivastava Sunita Singh Debajyoti Mohanty Nughat Hussain Source Type: research
Reply to: "Is Choosing Wisely Wise for Lobular Carcinoma in Patients Over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns
Ann Surg Oncol. 2023 Nov 28. doi: 10.1245/s10434-023-14563-4. Online ahead of print.NO ABSTRACTPMID:38017123 | DOI:10.1245/s10434-023-14563-4 (Source: Ann Oncol)
Source: Ann Oncol - November 28, 2023 Category: Cancer & Oncology Authors: Nicole Goldhaber Thomas O'Keefe Sarah Blair Source Type: research
Reply to: "Is Choosing Wisely Wise for Lobular Carcinoma in Patients Over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns
Ann Surg Oncol. 2023 Nov 28. doi: 10.1245/s10434-023-14563-4. Online ahead of print.NO ABSTRACTPMID:38017123 | DOI:10.1245/s10434-023-14563-4 (Source: Ann Oncol)
Source: Ann Oncol - November 28, 2023 Category: Cancer & Oncology Authors: Nicole Goldhaber Thomas O'Keefe Sarah Blair Source Type: research
Cancers, Vol. 15, Pages 5491: Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights
iela Raso
The second most common breast carcinoma, invasive lobular carcinoma, accounts for approximately 15% of tumors of breast origin. Its incidence has increased in recent times due in part to hormone replacement therapy and improvement in diagnostic modalities. Although believed to arise from the same cell type as their ductal counterpart, invasive lobular carcinomas (ILCs) are a distinct entity with different regulating genetic pathways, characteristic histologies, and different biology. The features most unique to lobular carcinomas include loss of E-Cadherin leading to discohesion and formation of a characteris...
Source: Cancers - November 20, 2023 Category: Cancer & Oncology Authors: Harsh Batra Jason Aboudi Mouabbi Qingqing Ding Aysegul A. Sahin Maria Gabriela Raso Tags: Review Source Type: research
Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment
ConclusionThe findings suggest that [177Lu]Lu-DOTAGA.FAPi dimer therapy is well-tolerated, safe, and effective for treating end-stage metastatic breast cancer patients. [177Lu]Lu-DOTAGA.FAPi dimer treatment demonstrated promising efficacy in patients with advanced breast cancer, as indicated by high disease control rates, favorable response outcomes, and acceptable safety profile. Further research and longer follow-up are warranted to assess long-term outcomes and validate these findings. (Source: European Journal of Nuclear Medicine and Molecular Imaging)
Source: European Journal of Nuclear Medicine and Molecular Imaging - November 7, 2023 Category: Nuclear Medicine Source Type: research
